Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Resistant Epithelial Ovarian Cancer”

413 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 413 results

Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Large-scale testing (Phase 3)Looking for participantsNCT07218809
What this trial is testing

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
AstraZeneca 1,100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06509971
What this trial is testing

QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital 39
Early research (Phase 1)Ended earlyNCT03608618
What this trial is testing

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Who this might be right for
Peritoneal MesotheliomaFallopian Tube AdenocarcinomaAdenocarcinoma of the Ovary+1 more
MaxCyte, Inc. 14
Testing effectiveness (Phase 2)Study completedNCT03268382
What this trial is testing

P53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Who this might be right for
High-grade Serous Ovarian Cancer
Aprea Therapeutics 36
Testing effectiveness (Phase 2)Looking for participantsNCT04787289
What this trial is testing

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Who this might be right for
Ovarian CancerPlatinum-resistant Ovarian Cancer
British Columbia Cancer Agency 244
Early research (Phase 1)Looking for participantsNCT07226427
What this trial is testing

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Stemline Therapeutics, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT05465941
What this trial is testing

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
Mayo Clinic 43
Early research (Phase 1)Study completedNCT03639246
What this trial is testing

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Aravive, Inc. 53
Large-scale testing (Phase 3)WithdrawnNCT03632798
What this trial is testing

Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
Cordgenics, LLC
Testing effectiveness (Phase 2)Ended earlyNCT04504916
What this trial is testing

Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Who this might be right for
Triple-negative Breast CancerNon-squamous Non-small-cell Lung CancerNSCLC+12 more
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 102
Testing effectiveness (Phase 2)Study completedNCT03206047
What this trial is testing

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
National Cancer Institute (NCI) 12
Early research (Phase 1)Looking for participantsNCT06586957
What this trial is testing

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc. 150
Large-scale testing (Phase 3)UnknownNCT05145218
What this trial is testing

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Who this might be right for
Recurrent Platinum-resistant Ovarian Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 405
Testing effectiveness (Phase 2)Study completedNCT02383251
What this trial is testing

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 118
Large-scale testing (Phase 3)Study completedNCT01196741
What this trial is testing

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
University College, London 107
Testing effectiveness (Phase 2)Study completedNCT01164995
What this trial is testing

Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

Who this might be right for
Epithelial Ovarian Cancer
The Netherlands Cancer Institute 24
Testing effectiveness (Phase 2)Study completedNCT02591095
What this trial is testing

ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant or Refractory Ovarian Cancer
Centre Francois Baclesse 47
Early research (Phase 1)Ended earlyNCT01227941
What this trial is testing

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Who this might be right for
Ovarian Cancer
Tesaro, Inc. 6
Testing effectiveness (Phase 2)Study completedNCT00945139
What this trial is testing

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Who this might be right for
Ovarian Cancer
New Mexico Cancer Research Alliance 46
Load More Results